The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives (Q57926685)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

article published in 2018

Language	Label	Description	Also known as
English	The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives	article published in 2018

Statements

scholarly article

0 references

The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives (English)

0 references

behavioral neuroscience

0 references

Karl Martin Klein

object named as

Karl Martin Klein

3

0 references

Susanne Schubert-Bast

object named as

Susanne Schubert-Bast

1

0 references

Adam Strzelczyk

object named as

Adam Strzelczyk

6

0 references

2

object named as

Felix Rosenow

0 references

4

object named as

Philipp S. Reif

0 references

Matthias Kieslich

5

object named as

Matthias Kieslich

0 references

publication date

June 2018

0 references

Epilepsy Behavior

0 references

Tuberous sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

mTOR in Brain Physiology and Pathologies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Impaired synaptic plasticity in a rat model of tuberous sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Cognitive prognosis of patients with tuberous sclerosis complex.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Cognitive impairment in tuberous sclerosis complex is a multifactorial condition

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Influence of seizures on early development in tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Clinical presentation and diagnosis of tuberous sclerosis complex in infancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Clinical Electroencephalographic Biomarker for Impending Epilepsy in Asymptomatic Tuberous Sclerosis Complex Infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Management of seizures in Lennox-Gastaut syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Tuberous sclerosis complex and the ketogenic diet

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Ketogenic Diet for the Management of Epilepsy Associated with Tuberous Sclerosis Complex in Children

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Predictors of seizure outcomes in children with tuberous sclerosis complex and intractable epilepsy undergoing resective epilepsy surgery: an individual participant data meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Epilepsy surgery in young children with tuberous sclerosis: results of a novel approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Rapamycin reduces seizure frequency in tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Everolimus treatment of refractory epilepsy in tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Early control of seizures improves long-term outcome in children with tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Early Detection of Tuberous Sclerosis Complex: An Opportunity for Improved Neurodevelopmental Outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Regression of Neonatal Cardiac Rhabdomyoma in Two Months Through Low-Dose Everolimus Therapy: A Report of Three Cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Accelerated Cardiac Rhabdomyoma Regression with Everolimus in Infants with Tuberous Sclerosis Complex.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Regression of massive cardiac rhabdomyoma on everolimus therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Early onset epileptic encephalopathy or genetically determined encephalopathy with early onset epilepsy? Lessons learned from TSC.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Dramatic relapse of seizures after everolimus withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Long-term treatment of epilepsy with everolimus in tuberous sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Prospective clinical trials to investigate clinical and molecular biomarkers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Identifiers

10.1016/J.YEBEH.2018.05.039

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57926685&oldid=2169315435"